We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Enzymatic Degradation of Pyocyanin Blocks Pseudomonas Biofilm Formation

By LabMedica International staff writers
Posted on 20 Dec 2016
An enzyme isolated from the soil bacterium Mycobacterium fortuitum was found to prevent biofilm formation by the aggressively pathogenic Gram-negative bacterium Pseudomonas aeruginosa.

P. More...
aeruginosa biofilms can develop as chronic opportunistic infections, which are a serious problem for medical care, especially for immunocompromised patients and the elderly. Biofilms often cannot be treated effectively with traditional antibiotic therapy, as they seem to protect bacteria from adverse environmental factors.

Pyocyanin is one of the many toxins produced and secreted by P. aeruginosa. It is a blue, secondary metabolite with the ability to oxidize and reduce other molecules and therefore can kill microbes competing against P. aeruginosa as well as mammalian cells of the lungs, which P. aeruginosa has infected during cystic fibrosis.

Investigators at the California Institute of Technology (Pasadena, USA) and the University of Oxford (United Kingdom) described in the December 8, 2016, online edition of the journal Science the discovery of an enzyme isolated from Mycobacterium fortuitum that oxidized the pyocyanin methyl group to formaldehyde and reduced the pyrazine ring via an unusual tautomerizing demethylation reaction.

Treatment of P. aeruginosa with this pyocyanin demethylase (PodA) enzyme disrupted biofilm formation.

"Pseudomonas aeruginosa causes chronic infections that are difficult to treat, such as those that inhabit burn wounds, diabetic ulcers, and the lungs of individuals living with cystic fibrosis," said senior author Dr. Dianne Newman, professor of biology and geobiology at the California Institute of Technology. "In part, the reason these infections are hard to treat is because P. aeruginosa enters a biofilm mode of growth in these contexts; biofilms tolerate conventional antibiotics much better than other modes of bacterial growth. Our research suggests a new approach to inhibiting P. aeruginosa biofilms."

"What is interesting about this result from an ecological perspective is that a potential new therapeutic approach comes from leveraging reactions catalyzed by soil bacteria," said Dr. Newman. "These organisms likely co-evolved with the pathogen, and we may simply be harnessing strategies other microbes use to keep it in check in nature. The chemical dynamics between microorganisms are fascinating, and we have so much more to learn before we can best exploit them."

Related Links:
California Institute of Technology
University of Oxford

New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.